Copyright Reports & Markets. All rights reserved.

Global Macular Degeneration Drug Pipeline Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Gene therapy
    • 1.2.3 Small molecules
    • 1.2.4 Stem cell therapy
    • 1.2.5 Gene therapies
  • 1.3 Market by Application
    • 1.3.1 Global Macular Degeneration Drug Pipeline Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hospital
    • 1.3.3 Research Institute
    • 1.3.4 Commercial
    • 1.3.5 Other
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Macular Degeneration Drug Pipeline Market Perspective (2016-2027)
  • 2.2 Macular Degeneration Drug Pipeline Growth Trends by Regions
    • 2.2.1 Macular Degeneration Drug Pipeline Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Macular Degeneration Drug Pipeline Historic Market Share by Regions (2016-2021)
    • 2.2.3 Macular Degeneration Drug Pipeline Forecasted Market Size by Regions (2022-2027)
  • 2.3 Macular Degeneration Drug Pipeline Industry Dynamic
    • 2.3.1 Macular Degeneration Drug Pipeline Market Trends
    • 2.3.2 Macular Degeneration Drug Pipeline Market Drivers
    • 2.3.3 Macular Degeneration Drug Pipeline Market Challenges
    • 2.3.4 Macular Degeneration Drug Pipeline Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue
    • 3.1.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue (2016-2021)
    • 3.1.2 Global Macular Degeneration Drug Pipeline Revenue Market Share by Players (2016-2021)
  • 3.2 Global Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Macular Degeneration Drug Pipeline Revenue
  • 3.4 Global Macular Degeneration Drug Pipeline Market Concentration Ratio
    • 3.4.1 Global Macular Degeneration Drug Pipeline Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drug Pipeline Revenue in 2020
  • 3.5 Macular Degeneration Drug Pipeline Key Players Head office and Area Served
  • 3.6 Key Players Macular Degeneration Drug Pipeline Product Solution and Service
  • 3.7 Date of Enter into Macular Degeneration Drug Pipeline Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Macular Degeneration Drug Pipeline Breakdown Data by Type

  • 4.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Type (2016-2021)
  • 4.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2022-2027)

5 Macular Degeneration Drug Pipeline Breakdown Data by Application

  • 5.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Application (2016-2021)
  • 5.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Macular Degeneration Drug Pipeline Market Size (2016-2027)
  • 6.2 North America Macular Degeneration Drug Pipeline Market Size by Type
    • 6.2.1 North America Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
    • 6.2.2 North America Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
    • 6.2.3 North America Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
  • 6.3 North America Macular Degeneration Drug Pipeline Market Size by Application
    • 6.3.1 North America Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
    • 6.3.2 North America Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
    • 6.3.3 North America Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
  • 6.4 North America Macular Degeneration Drug Pipeline Market Size by Country
    • 6.4.1 North America Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
    • 6.4.2 North America Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Macular Degeneration Drug Pipeline Market Size (2016-2027)
  • 7.2 Europe Macular Degeneration Drug Pipeline Market Size by Type
    • 7.2.1 Europe Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
    • 7.2.2 Europe Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
    • 7.2.3 Europe Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
  • 7.3 Europe Macular Degeneration Drug Pipeline Market Size by Application
    • 7.3.1 Europe Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
    • 7.3.2 Europe Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
    • 7.3.3 Europe Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
  • 7.4 Europe Macular Degeneration Drug Pipeline Market Size by Country
    • 7.4.1 Europe Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
    • 7.4.2 Europe Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size (2016-2027)
  • 8.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type
    • 8.2.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application
    • 8.3.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region
    • 8.4.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Macular Degeneration Drug Pipeline Market Size (2016-2027)
  • 9.2 Latin America Macular Degeneration Drug Pipeline Market Size by Type
    • 9.2.1 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
    • 9.2.2 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
    • 9.2.3 Latin America Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
  • 9.3 Latin America Macular Degeneration Drug Pipeline Market Size by Application
    • 9.3.1 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
    • 9.3.2 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
    • 9.3.3 Latin America Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
  • 9.4 Latin America Macular Degeneration Drug Pipeline Market Size by Country
    • 9.4.1 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
    • 9.4.2 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size (2016-2027)
  • 10.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type
    • 10.2.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application
    • 10.3.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country
    • 10.4.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Amgen
    • 11.1.1 Amgen Company Details
    • 11.1.2 Amgen Business Overview
    • 11.1.3 Amgen Macular Degeneration Drug Pipeline Introduction
    • 11.1.4 Amgen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.1.5 Amgen Recent Development
  • 11.2 Roche
    • 11.2.1 Roche Company Details
    • 11.2.2 Roche Business Overview
    • 11.2.3 Roche Macular Degeneration Drug Pipeline Introduction
    • 11.2.4 Roche Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.2.5 Roche Recent Development
  • 11.3 Adverum Biotechnologies
    • 11.3.1 Adverum Biotechnologies Company Details
    • 11.3.2 Adverum Biotechnologies Business Overview
    • 11.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Introduction
    • 11.3.4 Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.3.5 Adverum Biotechnologies Recent Development
  • 11.4 AsclepiX Therapeutics
    • 11.4.1 AsclepiX Therapeutics Company Details
    • 11.4.2 AsclepiX Therapeutics Business Overview
    • 11.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Introduction
    • 11.4.4 AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.4.5 AsclepiX Therapeutics Recent Development
  • 11.5 Bioeq AG
    • 11.5.1 Bioeq AG Company Details
    • 11.5.2 Bioeq AG Business Overview
    • 11.5.3 Bioeq AG Macular Degeneration Drug Pipeline Introduction
    • 11.5.4 Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.5.5 Bioeq AG Recent Development
  • 11.6 Sinocelltech
    • 11.6.1 Sinocelltech Company Details
    • 11.6.2 Sinocelltech Business Overview
    • 11.6.3 Sinocelltech Macular Degeneration Drug Pipeline Introduction
    • 11.6.4 Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.6.5 Sinocelltech Recent Development
  • 11.7 RemeGen
    • 11.7.1 RemeGen Company Details
    • 11.7.2 RemeGen Business Overview
    • 11.7.3 RemeGen Macular Degeneration Drug Pipeline Introduction
    • 11.7.4 RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.7.5 RemeGen Recent Development
  • 11.8 Grifols, S.A.
    • 11.8.1 Grifols, S.A. Company Details
    • 11.8.2 Grifols, S.A. Business Overview
    • 11.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Introduction
    • 11.8.4 Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.8.5 Grifols, S.A. Recent Development
  • 11.9 Kyowa Kirin
    • 11.9.1 Kyowa Kirin Company Details
    • 11.9.2 Kyowa Kirin Business Overview
    • 11.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Introduction
    • 11.9.4 Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.9.5 Kyowa Kirin Recent Development
  • 11.10 EyePoint Pharmaceutical
    • 11.10.1 EyePoint Pharmaceutical Company Details
    • 11.10.2 EyePoint Pharmaceutical Business Overview
    • 11.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Introduction
    • 11.10.4 EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.10.5 EyePoint Pharmaceutical Recent Development
  • 11.11 IVERIC Bio
    • 11.11.1 IVERIC Bio Company Details
    • 11.11.2 IVERIC Bio Business Overview
    • 11.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Introduction
    • 11.11.4 IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.11.5 IVERIC Bio Recent Development
  • 11.12 Kodiak Sciences
    • 11.12.1 Kodiak Sciences Company Details
    • 11.12.2 Kodiak Sciences Business Overview
    • 11.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Introduction
    • 11.12.4 Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.12.5 Kodiak Sciences Recent Development
  • 11.13 Ribomic
    • 11.13.1 Ribomic Company Details
    • 11.13.2 Ribomic Business Overview
    • 11.13.3 Ribomic Macular Degeneration Drug Pipeline Introduction
    • 11.13.4 Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.13.5 Ribomic Recent Development
  • 11.14 Lineage Cell Therapeutics
    • 11.14.1 Lineage Cell Therapeutics Company Details
    • 11.14.2 Lineage Cell Therapeutics Business Overview
    • 11.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Introduction
    • 11.14.4 Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.14.5 Lineage Cell Therapeutics Recent Development
  • 11.15 Graybug Vision
    • 11.15.1 Graybug Vision Company Details
    • 11.15.2 Graybug Vision Business Overview
    • 11.15.3 Graybug Vision Macular Degeneration Drug Pipeline Introduction
    • 11.15.4 Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.15.5 Graybug Vision Recent Development
  • 11.16 CHABiotech
    • 11.16.1 CHABiotech Company Details
    • 11.16.2 CHABiotech Business Overview
    • 11.16.3 CHABiotech Macular Degeneration Drug Pipeline Introduction
    • 11.16.4 CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.16.5 CHABiotech Recent Development
  • 11.17 Shanghai Henlius Biotech
    • 11.17.1 Shanghai Henlius Biotech Company Details
    • 11.17.2 Shanghai Henlius Biotech Business Overview
    • 11.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Introduction
    • 11.17.4 Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.17.5 Shanghai Henlius Biotech Recent Development
  • 11.18 Bio-Thera Solutions
    • 11.18.1 Bio-Thera Solutions Company Details
    • 11.18.2 Bio-Thera Solutions Business Overview
    • 11.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Introduction
    • 11.18.4 Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
    • 11.18.5 Bio-Thera Solutions Recent Development
  • 11.18 Alteogen

.1 Alteogen Company Details

    .2 Alteogen Business Overview

      .3 Alteogen Macular Degeneration Drug Pipeline Introduction

        .4 Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)

          .5 Alteogen Recent Development

          • 11.20 Outlook Therapeutics
            • 11.20.1 Outlook Therapeutics Company Details
            • 11.20.2 Outlook Therapeutics Business Overview
            • 11.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Introduction
            • 11.20.4 Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2016-2021)
            • 11.20.5 Outlook Therapeutics Recent Development

          12 Analyst's Viewpoints/Conclusions

            13 Appendix

            • 13.1 Research Methodology
              • 13.1.1 Methodology/Research Approach
              • 13.1.2 Data Source
            • 13.2 Disclaimer

            Global Macular Degeneration Drug Pipeline Scope and Market Size
            Macular Degeneration Drug Pipeline market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Macular Degeneration Drug Pipeline market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

            Segment by Type
            Gene therapy
            Small molecules
            Stem cell therapy
            Gene therapies

            Segment by Application
            Hospital
            Research Institute
            Commercial
            Other

            By Region
            North America
            United States
            Canada
            Europe
            Germany
            France
            U.K.
            Italy
            Russia
            Nordic
            Rest of Europe
            Asia-Pacific
            China
            Japan
            South Korea
            Southeast Asia
            India
            Australia
            Rest of Asia
            Latin America
            Mexico
            Brazil
            Rest of Latin America
            Middle East & Africa
            Turkey
            Saudi Arabia
            UAE
            Rest of MEA

            By Company
            Amgen
            Roche
            Adverum Biotechnologies
            AsclepiX Therapeutics
            Bioeq AG
            Sinocelltech
            RemeGen
            Grifols, S.A.
            Kyowa Kirin
            EyePoint Pharmaceutical
            IVERIC Bio
            Kodiak Sciences
            Ribomic
            Lineage Cell Therapeutics
            Graybug Vision
            CHABiotech
            Shanghai Henlius Biotech
            Bio-Thera Solutions
            Alteogen
            Outlook Therapeutics

            Buy now